CIBC Private Wealth Group
ESPR

CIBC Private Wealth Group’s Esperion Therapeutics ESPR Stock Holding History

CIBC Private Wealth Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,700
Closed -$67K – 1178
2018
Q2 		$67K Buy
1,700
+700
+70% +$35.4K ﹤0.01% 1101
2018
Q1 		$72K Buy
+1,000
New +$73.4K ﹤0.01% 1084

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CIBC Private Wealth Group's ESPR Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 1,700 shares — an estimated $67K sold.

CIBC Private Wealth Group first reported a position in ESPR in Q1 2018 and held it in 2 quarters. The position peaked at $72K in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 1,700 Esperion Therapeutics shares in Q3 2018, an estimated $67K.
  • CIBC Private Wealth Group first reported a position in Esperion Therapeutics in Q1 2018 and held it in 2 quarters.
  • CIBC Private Wealth Group's Esperion Therapeutics position peaked at $72K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.